FDA Opted Not to Approve Neffy Yet
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Sept. 20, 2023 -- In a surprising move, the U.S. Food and Drug Administration has opted not to approve a needle-free alternative to the EpiPen for emergency treatment of severe allergic reactions.
Approval of the Neffy (epinephrine) nasal spray was widely anticipated. An FDA advisory panel voted to recommend approval of the drug for children and adults in May. While the FDA is not obligated to follow the advice of its advisory panels, it usually does. Instead, the FDA told the drug's maker, ARS Pharmaceuticals, that it needed to conduct another study on the drug before it is approved, the company said in a statement late Tuesday night.
"We are deeply disappointed that this action further delays the availability of Neffy for the millions of people who are at risk of a potentially life-threatening severe allergic reaction," said Richard Lowenthal, cofounder, president, and CEO of ARS Pharma.
"We stand by the totality of the Neffy data package in a comprehensive registration program that was aligned upon with FDA and believe strongly in the value Neffy can provide for patients, families, and caregivers living daily with severe allergic reactions," he said in a company statement, adding that his firm will aim to complete the requested trial as soon as possible.
The news was unwelcome on the front lines of health care. "It's certainly disappointing as we were hoping to have another option for people at risk of severe allergic reactions," Scott Sicherer, M.D., director of the Elliot and Roslyn Jaffe Food Allergy Institute at Mount Sinai in New York City, told HealthDay.
"Neffy would have been the first needle-free option for patients to treat severe allergic reactions, but we still have the injectable epinephrine devices available," Payel Gupta, M.D., an assistant clinical professor at SUNY Downstate Medical Center in New York City and volunteer medical spokeswoman for the American Lung Association, told HealthDay. "A needle-free option would be great for people with needle phobia or who are anxious about injecting themselves."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Recommendations Developed to Prepare Patients for Oral Immunotherapy
FRIDAY, April 19, 2024 -- In a research article published online April 8 in the Journal of Allergy and Clinical Immunology, consensus recommendations are presented for preparing...
Penicillin Allergy Can Be Delabeled by Nonallergy Providers
TUESDAY, April 9, 2024 -- Direct oral penicillin challenges (DPCs) can be delivered to patients with penicillin allergy labels (PALs) by nonallergy health care professionals...
American Academy of Allergy, Asthma & Immunology, Feb. 23 to 26
The annual meeting of the American Academy of Allergy, Asthma & Immunology was held from Feb. 23 to 26 in Washington, D.C., drawing participants from around the world...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.